The patient received three once weekly doses of FT500, and the treatment cycle was well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period, the company said in a statement.
FT500 is a natural killer cell cancer immunotherapy. It is the first-ever cell therapy derived from an "induced pluripotent stem cell" (iPSC) administered to a patient in the US.
The company said that new preclinical data of universal, off-the-shelf, iPSC-derived NK cell product candidates -- FT516 and FT596 -- have also been highlighted at the 2019 AACR (American Association for Cancer Research) annual meeting.
Price: 17.56, Change: -0.01, Percent Change: -0.06
|Analysts Reduce Alleghany Corp's Q2, 2019, and 2020 ...|
|2019, and 2020 Estimates for United States Steel Low...|
|Extraction Oil & Gas' 2019, 2020, and Q2 Earnings Es...|
|Earnings Estimate for Viper Energy Partners in 2020 ...|
|Westlake Chemical's 2019, 2020, and Q2 Earnings Esti...|